ANSWER: D

Rationale:

Propranolol undergoes extensive first-pass hepatic metabolism — approximately 60–70% of an oral dose is extracted by the liver before reaching the systemic circulation, resulting in oral bioavailability of approximately 25% that is highly variable between individuals due to differences in hepatic CYP2D6 and CYP1A2 activity. This means that oral doses must be substantially higher than IV doses to achieve equivalent plasma concentrations, and dose titration must account for significant inter-individual variability. This first-pass effect also means that conditions reducing hepatic blood flow (cirrhosis, heart failure with reduced cardiac output) can dramatically increase propranolol bioavailability.

• Option A: Option A is incorrect because atenolol is hydrophilic and is not significantly metabolized by the liver; it is renally excreted with bioavailability of approximately 50% that is relatively consistent.
• Option B: Option B is incorrect because bisoprolol has approximately 90% oral bioavailability with minimal first-pass metabolism.
• Option C: Option C is incorrect because nadolol is hydrophilic, minimally metabolized, and renally excreted with bioavailability of approximately 30–40% but without extensive first-pass extraction.
• Option E: Option E is incorrect because while carvedilol does undergo first-pass metabolism, propranolol's first-pass effect is the most clinically significant and historically important of the listed options.

ANSWER: A

Rationale:

In peripheral vasculature, both alpha-1 and beta-2 adrenoceptors regulate vascular tone. Alpha-1 receptors mediate sympathetic vasoconstriction; beta-2 receptors mediate vasodilation in skeletal muscle vasculature. Under normal physiological conditions, these opposing effects are in dynamic balance. Non-selective beta-blockers such as propranolol, nadolol, and carvedilol block beta-2 receptors in peripheral vascular smooth muscle, removing the vasodilatory tone. This leaves alpha-1-mediated vasoconstriction unopposed, reducing blood flow to the extremities and skeletal muscle. In patients with peripheral arterial disease who already have compromised limb perfusion from atherosclerotic obstruction, this additional vasoconstrictive effect reduces the already-limited collateral blood flow, worsening claudication distance and causing cold extremities. Cardioselective beta-blockers (bisoprolol, metoprolol, atenolol) have less effect on peripheral beta-2 receptors and are better tolerated in patients with mild-to-moderate peripheral arterial disease.

• Option B: Option B is incorrect because while reduced cardiac output does lower perfusion pressure, the primary mechanism of peripheral symptom worsening is the beta-2-mediated vasoconstrictive shift, not the systemic pressure reduction.
• Option C: Option C is incorrect because beta-2 receptors do not regulate oxygen-hemoglobin dissociation in skeletal muscle; that is determined by local pH, PCO2, and temperature.
• Option D: Option D is incorrect because the membrane-stabilizing effect of beta-blockers is a direct myocardial action relevant to antiarrhythmic activity, not peripheral vasoconstriction.
• Option E: Option E is incorrect because reduced renin and angiotensin II would produce vasodilation, not impair autoregulation in a way that worsens peripheral ischemia.

ANSWER: C

Rationale:

Phenoxybenzamine is a non-competitive, irreversible alpha-adrenoceptor antagonist — it covalently alkylates alpha-1 (and alpha-2) receptors, permanently inactivating them. New receptor-mediated vasoconstriction can only occur as new receptors are synthesized over days. This irreversibility is the critical pharmacological advantage in pheochromocytoma: during surgical manipulation of the tumor, massive boluses of catecholamines are released into the circulation. A competitive alpha-blocker such as phentolamine can be displaced from its receptor binding site by these overwhelming catecholamine concentrations through mass action, resulting in breakthrough hypertensive surges. Phenoxybenzamine, being covalently bound, cannot be displaced regardless of the catecholamine concentration — providing reliable alpha blockade even during the most intense surges. Phenoxybenzamine is typically started 10–14 days preoperatively to allow adequate alpha blockade and volume expansion (which reverses the volume contraction caused by chronic catecholamine-mediated vasoconstriction). Phentolamine IV is used intraoperatively for acute breakthrough hypertensive episodes when short-acting, titratable control is needed.

• Option A: Option A is incorrect because phenoxybenzamine is non-selective (blocks both alpha-1 and alpha-2), not selectively alpha-1; phentolamine is also non-selective.
• Option B: Option B is incorrect because phenoxybenzamine has a much longer duration of action than phentolamine; the duration advantage is reversed.
• Option D: Option D is incorrect because phenoxybenzamine does not selectively target adrenal chromaffin cell receptors; it blocks all alpha receptors peripherally.
• Option E: Option E is incorrect because phenoxybenzamine does not have beta-blocking activity.

ANSWER: B

Rationale:

The combination of a beta-blocker with a non-dihydropyridine CCB — verapamil or diltiazem — produces additive pharmacodynamic depression of the cardiac conduction system. Beta-1 blockade slows sinus node automaticity and AV nodal conduction velocity; verapamil and diltiazem have the same effects through L-type calcium channel blockade in nodal tissue. When combined, these additive effects on the AV node can produce severe bradycardia, prolonged PR interval, second- or third-degree AV block, and hemodynamic compromise — particularly in patients with pre-existing conduction disease or impaired ventricular function. Both verapamil and diltiazem share this risk — the interaction is a class effect of non-DHP CCBs, not selective to verapamil. This combination is either contraindicated or used only with extreme caution and close monitoring (for example, in patients with atrial fibrillation requiring rate control where other options have failed). Dihydropyridine CCBs (amlodipine, felodipine, nifedipine) do not have significant cardiac nodal effects and can be safely combined with beta-blockers.

• Option A: Option A is incorrect because the interaction is pharmacodynamic (additive receptor-level effects), not primarily pharmacokinetic, and dose reduction alone does not eliminate the conduction risk.
• Option C: Option C is incorrect because the mechanism is AV nodal conduction suppression, not ryanodine receptor-mediated diastolic dysfunction.
• Option D: Option D is incorrect because the bradycardia and AV block risk exists in patients with normal sinus rhythm as well, and is not limited to those with atrial fibrillation.
• Option E: Option E is incorrect because diltiazem shares the AV nodal suppression risk with verapamil; both are contraindicated in combination with beta-blockers.

ANSWER: E

Rationale:

The distinction between hydrophilic and lipophilic beta-blockers has direct clinical relevance for patients with CKD. Atenolol and nadolol are hydrophilic — they have low lipid solubility, poor CNS penetration, and are predominantly eliminated by renal excretion as unchanged drug (atenolol approximately 85–100% renal; nadolol approximately 70% renal). In CKD, as GFR and tubular secretion decrease, these drugs accumulate — their half-lives extend significantly and plasma levels rise, increasing the risk of excessive bradycardia, AV block, and hypotension. Dose reduction and extended dosing intervals are required in proportion to the degree of renal impairment; atenolol is removed by hemodialysis and requires supplemental dosing after dialysis sessions. In contrast, metoprolol and propranolol are lipophilic — they are extensively metabolized by hepatic CYP enzymes (primarily CYP2D6 and CYP1A2) to inactive or less-active metabolites; renal excretion of unchanged drug is minimal. Their pharmacokinetics are therefore not significantly altered by renal impairment and dose adjustment for CKD alone is generally not required.

• Option A: Option A is incorrect because atenolol and nadolol do not accumulate through transporter-inhibition feedback mechanisms; their accumulation is simply from reduced renal elimination.
• Option B: Option B is incorrect because atenolol and nadolol are not glucuronidated in the kidney; they are excreted as unchanged drug.
• Option C: Option C is incorrect because atenolol and nadolol are not hepatically metabolized to active metabolites — they are renally excreted as parent drug.
• Option D: Option D is incorrect because not all beta-blockers require renal dose adjustment; the lipophilic hepatically-metabolized agents do not.

ANSWER: D

Rationale:

Nebivolol is a highly cardioselective beta-1 blocker with a unique vasodilatory mechanism that distinguishes it from all other clinically used beta-blockers. Its vasodilation is mediated through stimulation of endothelial beta-3 receptors, which activates endothelial nitric oxide synthase (eNOS), increasing the production of nitric oxide. NO diffuses to adjacent vascular smooth muscle cells, activates soluble guanylyl cyclase, raises cyclic GMP, and causes smooth muscle relaxation and vasodilation. This beta-3/eNOS/NO pathway is mechanistically distinct from the alpha-1 receptor blockade used by carvedilol and labetalol to produce vasodilation. Nebivolol's combination of cardioselective beta-1 blockade and NO-mediated vasodilation gives it a favorable hemodynamic profile with less peripheral vasoconstriction and a better metabolic adverse effect profile than non-vasodilatory beta-blockers.

• Option A: Option A is incorrect because nebivolol does not produce vasodilation through alpha-1 receptor blockade; that is the mechanism of carvedilol and labetalol.
• Option B: Option B is incorrect because nebivolol does not inhibit phosphodiesterase-3; that mechanism belongs to milrinone.
• Option C: Option C is incorrect because beta-2 receptor blockade causes vasoconstriction, not vasodilation; nebivolol's vasodilatory mechanism does not involve beta-2 receptors.
• Option E: Option E is incorrect because nebivolol does not inhibit ACE in vascular endothelium; it is not an ACE inhibitor.

ANSWER: A

Rationale:

Hydralazine-induced drug-induced lupus erythematosus (DILE) is a well-characterized adverse effect that is dose-dependent and strongly associated with slow acetylator phenotype. Hydralazine is metabolized in part by N-acetyltransferase 2 (NAT2) — individuals who are slow acetylators due to NAT2 polymorphisms metabolize hydralazine more slowly, resulting in higher and more sustained plasma levels for a given dose. This increased drug exposure drives the immune dysregulation underlying DILE. The risk increases significantly at doses above 200 mg daily and with prolonged duration of therapy. Clinical features of hydralazine-induced lupus include arthralgia, myalgia, pleuritis, pericarditis, and positive antinuclear antibody (ANA) — particularly anti-histone antibodies, which are characteristic of DILE. Unlike idiopathic lupus, hydralazine DILE typically does not involve the kidneys or central nervous system, and the syndrome resolves on drug discontinuation without requiring immunosuppressive therapy.

• Option B: Option B is incorrect because DILE can occur in patients without pre-existing autoimmune disease; it is not restricted to immunologically abnormal individuals.
• Option C: Option C is incorrect because DILE is not an IgE-mediated immediate hypersensitivity reaction; it is a delayed immune dysregulation syndrome unrelated to the first dose.
• Option D: Option D is incorrect because hydralazine DILE typically does not cause irreversible renal damage — renal and CNS involvement distinguishes idiopathic SLE from DILE; and the syndrome resolves without immunosuppressive therapy in most cases.
• Option E: Option E is incorrect because hydralazine is not a nitric oxide donor; its mechanism of vasodilation involves KATP channel opening and IP3 inhibition, not NO release.

ANSWER: C

Rationale:

The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) was a landmark study comparing chlorthalidone, amlodipine, lisinopril, and doxazosin in high-risk hypertensive patients. The doxazosin arm was stopped early by the Data Safety Monitoring Board after an interim analysis showed a significantly higher rate of combined cardiovascular disease events compared to chlorthalidone — most notably a doubling of the rate of heart failure hospitalizations and a 25% higher rate of combined cardiovascular events. Despite achieving comparable blood pressure lowering, doxazosin failed to provide the same degree of cardiovascular protection as chlorthalidone. The leading hypothesis is that thiazide-type diuretics offer cardiovascular benefits beyond blood pressure reduction — including volume control that reduces cardiac preload, favorable effects on vascular remodeling, and direct vascular protective mechanisms — that alpha-1 blockers do not replicate through vasodilation alone. This finding effectively ended the use of alpha-1 blockers as first-line antihypertensive therapy and relegated them to add-on therapy for resistant hypertension or as a secondary choice when a compelling indication (such as BPH) makes them useful.

• Option A: Option A is incorrect because doxazosin was not found to raise serum cholesterol; alpha-1 blockers actually have a mildly favorable lipid profile.
• Option B: Option B is incorrect because doxazosin does not cause AKI through afferent arteriolar constriction; it causes vasodilation.
• Option D: Option D is incorrect because alpha-1 blockers do not have significant direct cardiac conduction effects.
• Option E: Option E is incorrect because doxazosin did provide equivalent blood pressure lowering; the problem was lack of equivalent cardiovascular protection despite similar BP control.

ANSWER: B

Rationale:

Clonidine's adverse effects of sedation and dry mouth are mechanistically linked to its alpha-2 receptor activity. The alpha-2A receptor subtype in the locus coeruleus — a key noradrenergic nucleus in the brainstem that regulates arousal and attention — mediates clonidine's sedating properties; stimulation of alpha-2A receptors here reduces noradrenergic output to the cortex, producing sedation. Alpha-2 receptors in salivary glands mediate inhibition of salivary secretion, causing dry mouth. Moxonidine is more selective for imidazoline I1 receptors in the rostral ventrolateral medulla — the primary target for its antihypertensive effect — and has substantially lower affinity for alpha-2A receptors compared to clonidine. This lower alpha-2A receptor activity translates clinically into significantly less sedation and less dry mouth at equivalent antihypertensive doses. This improved tolerability profile is the primary pharmacological rationale for developing moxonidine as a second-generation centrally acting agent.

• Option A: Option A is incorrect because clonidine's sedation is not mediated by histamine H1 blockade, and its dry mouth is not mediated by muscarinic M3 blockade; both effects are alpha-2A mediated.
• Option C: Option C is incorrect because clonidine does not stimulate central beta-1 receptors; its sedation is alpha-2A mediated.
• Option D: Option D is incorrect because clonidine does not block dopamine D2 receptors; its sedation is through alpha-2A receptor stimulation in the locus coeruleus.
• Option E: Option E is incorrect because pharmacological and clinical data consistently show moxonidine produces less sedation and dry mouth than clonidine at equivalent antihypertensive doses.

ANSWER: E

Rationale:

Beta-blocker mortality benefit after MI is multi-mechanistic and operates across both the acute and chronic phases. In the acute and subacute peri-infarction period, elevated catecholamines from the stress response lower the threshold for ventricular fibrillation and other malignant arrhythmias in electrically unstable peri-infarction myocardium; beta-1 blockade suppresses this arrhythmogenic sympathetic drive. Reduced heart rate extends diastole, improving coronary perfusion to ischemic peri-infarction territories and reducing myocardial oxygen demand, potentially limiting infarct extension. Over the long term, chronic catecholamine exposure drives maladaptive ventricular remodeling through beta-1 receptor-coupled intracellular pathways — including PKA-mediated phospholamban hyperphosphorylation and CaMKII activation — that impair calcium handling, promote cardiomyocyte apoptosis, and drive pathological hypertrophy and fibrosis. Beta-1 blockade attenuates these pathways, slowing the progression to HFrEF after MI. The combined reduction in sudden cardiac death (arrhythmia mechanism) and progressive heart failure (remodeling mechanism) produces the observed mortality benefit. Option D is correct in its general outline but less mechanistically complete than E, which specifies the intracellular signaling pathways responsible for the remodeling component of mortality reduction.

• Option A: Option A is incorrect because while renin suppression is a component of beta-blocker pharmacology, it is not the primary mechanism of post-MI mortality benefit; ACEi/ARBs are the primary RAAS-targeting agents for post-MI remodeling.
• Option B: Option B is incorrect because post-MI beta-blocker benefit is not primarily mediated through beta-2 receptor blockade in cardiac fibroblasts.
• Option C: Option C is incorrect because the membrane-stabilizing property of some beta-blockers is a relatively minor pharmacological activity and is not the mechanism of clinical mortality reduction; it would apply only to high-dose propranolol in very specific contexts.

ANSWER: D

Rationale:

Pericardial effusion is a recognized adverse effect of minoxidil that occurs in approximately 3% of patients on long-term therapy. The mechanism is primarily related to the profound sodium and fluid retention that minoxidil causes through secondary RAAS activation (from baroreceptor-mediated sympathetic activation and reflex renin release) and direct renal sodium retention. This generalized fluid retention leads to accumulation of transudative fluid in the pericardial space. The transudative nature of the effusion is an important distinguishing feature — it is not inflammatory or exudative. Because the mechanism is fluid retention-related, intensification of diuretic therapy (typically escalating the loop diuretic dose) is the first-line management approach. If the effusion is large, causing hemodynamic compromise, or fails to respond to diuretic intensification, discontinuation of minoxidil and pericardiocentesis may be required. This complication underscores the importance of adequate diuretic co-therapy when minoxidil is used.

• Option A: Option A is incorrect because minoxidil-associated pericardial effusion is not an immune-mediated lupus-like phenomenon; it is fluid retention-related and does not require immunosuppressive therapy.
• Option B: Option B is incorrect because minoxidil does not have alpha-1 blocking properties; its mechanism is KATP channel opening in vascular smooth muscle.
• Option C: Option C is incorrect because the effusion is transudative, not exudative; it is not caused by direct pericardial capillary toxicity and does not invariably require pericardiocentesis.
• Option E: Option E is incorrect because KATP channels are not expressed in pericardial fibroblasts in a clinically relevant way that would produce this effect; the mechanism is systemic fluid retention, not local pericardial secretion.

ANSWER: A

Rationale:

The distinction between metoprolol succinate (extended-release) and metoprolol tartrate (immediate-release) in HFrEF is clinically and pharmacologically important. Metoprolol tartrate, when taken twice or three times daily, produces peak plasma concentrations followed by troughs — creating fluctuating levels of beta-1 blockade. In the vulnerable HFrEF myocardium, peak-concentration episodes of intense beta-1 blockade can acutely reduce contractility and cardiac output, potentially precipitating or worsening decompensation. Metoprolol succinate's extended-release mechanism produces smoother, more sustained plasma concentrations with reduced peak-to-trough variation, providing more hemodynamically consistent beta-1 blockade that is better tolerated. Critically, the landmark MERIT-HF trial — which demonstrated a 34% reduction in all-cause mortality and a 41% reduction in sudden cardiac death in HFrEF — used specifically the succinate extended-release formulation. Metoprolol tartrate has not been shown in an adequately powered randomized controlled trial to provide equivalent mortality reduction in HFrEF. This outcome evidence distinction, combined with the pharmacokinetic rationale, makes succinate the required formulation for HFrEF.

• Option B: Option B is incorrect because both metoprolol succinate and tartrate are beta-1 selective; neither is beta-2 selective.
• Option C: Option C is incorrect because metoprolol succinate does not have an active metabolite with alpha-1 blocking properties; it remains a pure beta-1 selective blocker.
• Option D: Option D is incorrect because both formulations contain the same active moiety (metoprolol) and both are metabolized primarily by CYP2D6; the difference is in release kinetics, not metabolic pathway.
• Option E: Option E is incorrect because the formulations are not therapeutically interchangeable in HFrEF; the outcome evidence specifically supports succinate and the pharmacokinetic rationale supports its superiority in this indication.

ANSWER: C

Rationale:

The transdermal clonidine patch (TTS-clonidine) has a pharmacokinetic profile that is fundamentally different from oral clonidine in terms of onset. After initial application, the drug must diffuse through the skin and accumulate in a subcutaneous depot before achieving steady-state delivery into the systemic circulation — this process takes approximately 48 hours (range 2–3 days). This delayed onset means the patch cannot be used to acutely control blood pressure; patients who have abruptly stopped oral clonidine and are experiencing withdrawal syndrome cannot rely on a newly applied patch to restore therapeutic levels quickly enough to prevent a hypertensive crisis. In that situation, restarting oral clonidine or using IV labetalol for acute control is necessary. The patch's advantages lie in long-term use: once steady state is achieved, it provides smooth, continuous clonidine delivery over 7 days with minimal peak-to-trough variation, improving adherence in patients who struggle with multiple daily oral doses.

• Option A: Option A is incorrect because while the patch does provide smoother plasma concentrations than oral dosing, the reasoning about first-pass metabolism is not clinically relevant for clonidine — the oral bioavailability of clonidine is already approximately 75–95% with modest first-pass effect.
• Option B: Option B is incorrect because the patch takes 48 hours, not 2 hours, to achieve therapeutic levels; it is definitively not appropriate for hypertensive emergencies.
• Option D: Option D is incorrect because there is no anatomical restriction to chest wall application; the patch can be applied to non-irritated skin in various locations.
• Option E: Option E is incorrect because rebound hypertension can still occur when a transdermal patch is removed — the gradual decline is slower than with oral discontinuation, but the same mechanism of central sympathetic re-activation can occur with delayed onset.

ANSWER: B

Rationale:

Beta-blockers control ventricular rate in atrial fibrillation by blocking beta-1 adrenoceptors at the AV node. This reduces the velocity of conduction through the AV node and prolongs the AV nodal refractory period, limiting the number of atrial impulses that are transmitted to the ventricle. The key clinical advantage over digoxin is the response to exercise and sympathetic activation. Digoxin controls ventricular rate primarily through a vagotonic mechanism (it enhances vagal tone via the nucleus ambiguus and sensitizes the AV node to acetylcholine) — this vagal effect is most effective at rest when parasympathetic tone predominates. During exercise or emotional stress, the surge in sympathetic activity overwhelms digoxin's vagally-dependent rate control, and ventricular rates can rise dramatically. Beta-blockers, by directly blocking the sympathetic drive to the AV node, maintain effective rate control during exercise as well as at rest. This makes beta-blockers (and non-DHP CCBs) the preferred rate control agents in active patients with AF, while digoxin may be reserved for sedentary patients or as an add-on agent.

• Option A: Option A is incorrect because beta-blockers do not block sodium channels to control AV nodal conduction; their mechanism is beta-1 adrenoceptor blockade.
• Option C: Option C is incorrect because beta-blockers are rate control agents, not rhythm control agents; they do not restore sinus rhythm in the majority of AF patients.
• Option D: Option D is incorrect because beta-blockers and digoxin have entirely different mechanisms; beta-blockers do not increase vagal tone.
• Option E: Option E is incorrect because rate control in AF with adequate heart rates generally improves rather than worsens cardiac output; beta-blockers are a first-line rate control option in AF.

ANSWER: E

Rationale:

The H-ISDN combination achieves complementary hemodynamic benefits through distinct mechanisms. Isosorbide dinitrate is an organic nitrate that is bioactivated (primarily through mitochondrial ALDH2) to release nitric oxide. NO activates soluble guanylyl cyclase, raising cyclic GMP and causing smooth muscle relaxation. Critically, organic nitrates have preferential venodilatory effects at clinical doses — they dilate venous capacitance vessels more than arterioles, reducing venous return, right atrial pressure, and pulmonary capillary wedge pressure (reducing preload). Hydralazine is a direct arteriolar vasodilator that reduces peripheral resistance and aortic impedance (reducing afterload). Together they address both loading conditions — the primary hemodynamic abnormalities in HFrEF. Additionally, hydralazine has antioxidant properties that reduce superoxide-mediated inactivation of mitochondrial ALDH2 and prevention of reactive oxygen species-mediated nitrate tolerance. With chronic nitrate use, ALDH2 becomes inactivated through oxidative stress, causing nitrate tolerance. Hydralazine's antioxidant effect preserves ALDH2 function, maintaining nitrate bioactivation and preventing tolerance — extending the hemodynamic efficacy of isosorbide dinitrate with chronic use. Option D is correct in identifying the nitrate tolerance mechanism but reverses which agent addresses which loading condition — hydralazine reduces afterload (not preload), and isosorbide dinitrate reduces preload (not afterload).

• Option A: Option A is incorrect because it reverses the mechanisms — hydralazine dilates arterioles (reducing afterload), not veins; isosorbide dinitrate dilates veins (reducing preload), not arterioles primarily.
• Option B: Option B is incorrect for the same reason — isosorbide dinitrate does not primarily reduce afterload and hydralazine does not cause renal sodium excretion.
• Option C: Option C is incorrect because isosorbide dinitrate preferentially dilates veins, not arterioles; and preload is significantly affected by the nitrate component.

ANSWER: D

Rationale:

Autonomic dysreflexia in spinal cord injury above T6 produces an uncontrolled sympathetic surge — typically triggered by a noxious stimulus below the level of injury (distended bladder, bowel impaction, pressure sore) — causing sudden severe hypertension through generalized alpha-1-mediated vasoconstriction below the injury level. The cardiovascular response also includes reflex bradycardia from baroreceptor activation (vagal response to hypertension) and sometimes reflex tachycardia during the initial sympathetic surge. IV labetalol's combined alpha-1 and beta-1 blockade is pharmacologically well-suited to this scenario: the alpha-1 blockade rapidly reduces the sympathetically-driven peripheral vasoconstriction causing the hypertension, while the beta-1 blockade can address any tachycardic component. However, the reflex bradycardia component of dysreflexia means that the beta-blocking component of labetalol must be used carefully — if significant bradycardia is already present, pure alpha-blockade with phentolamine or a short-acting agent like nitroprusside may be preferable. The definitive treatment is always removal of the triggering stimulus. Option A is not entirely incorrect in its reasoning about bradycardia risk, but phentolamine is not universally preferred over labetalol — the choice depends on the clinical presentation.

• Option B: Option B is incorrect because labetalol's beta-2 blockade causes bronchoconstriction, not bronchodilation; and bronchospasm is not a primary feature of autonomic dysreflexia.
• Option C: Option C is incorrect because phentolamine is not the universal first-line agent for all hypertensive emergencies; agent selection is clinical context-dependent.
• Option E: Option E is incorrect because labetalol is not contraindicated in dysreflexia; while cautious use is warranted if bradycardia is significant, the drug is frequently and appropriately used in this setting.